Krsnaa Diagnostics Limited reported a profit after tax (PAT) of ₹1,014 million for the financial year ended March 31, 2026, marking a 31% increase from the previous year. Revenue from operations for FY26 stood at ₹7,728 million, while EBITDA grew to ₹2,149 million with margins of 27.81%. The Board of Directors has recommended a dividend of ₹2 per share, representing 40% of the face value. The disclosures were made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company achieved its highest-ever quarterly collection in Q4 FY26 at ₹1,580 million, contributing to total half-year collections of ₹2,910 million. Days sales outstanding (DSO) improved to 139 days by the end of Q4, down from 155 days in the previous quarter. The retail business segment grew sixfold, scaling from ₹10 crores in FY25 to ₹60 crores in FY26, now contributing approximately 8% to total revenue.

Operational Expansion

Krsnaa Diagnostics operates 190-plus CT and MRI centers and 147 pathology laboratories, supported by over 4,700 patient collection centers across 18 states. The company processed nearly 59 million tests and served approximately 20 million patients during the year. Management highlighted a long-term revenue visibility of ₹6,000 crores to ₹7,000 crores over the next 5 to 7 years from existing operations and newly secured business.

Strategic Outlook

The company has planned a capital investment of ₹5,000 million for FY27, covering commitments from Rajasthan projects, radiology expansions, and retail infrastructure. The Rajasthan project is expected to contribute revenues starting Q1 FY27, with a full-year potential estimated between ₹100 crores and ₹150 crores. Management aims to reduce DSO to sub-120 days in FY27 and maintain EBITDA margins at current levels despite ramp-up costs.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE08LI01020/f94e67b89e874b34.pdf

Krsnaa Diagnostics Limited reported a consolidated net profit of ₹1,014.31 million for the financial year ended March 31, 2026, a 31% increase compared to the previous year. Revenue from operations for FY26 stood at ₹7,727.74 million, up from ₹7,171.60 million in FY25. The reported PAT includes a fair valuation gain of ₹222.41 million from the investment in Apulki Healthcare Private Limited. The board has recommended a final dividend of ₹2 per equity share, representing 40% of the face value, subject to shareholder approval.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹417.18 million on revenue from operations of ₹1,926.04 million, compared to a net profit of ₹206.78 million on revenue of ₹1,860.76 million in the corresponding quarter of the previous year. EBITDA for the quarter stood at ₹549 million versus ₹530 million in the same period last year, while the EBITDA margin came in at 29% compared to 29% year-on-year.

The following table summarises the key quarterly and full-year financial metrics:

Operational Highlights and Expansion

Operating cash flows strengthened significantly to ₹1,430.98 million in FY26 compared to ₹873.27 million in FY25. The retail diagnostics vertical, Krsnaa Retail Private Limited, delivered an 8 times jump in revenue and a 7 times surge in touchpoints, expanding to 3,500 locations across 5 states. A total of 51 centers and 1,167 collection centers were operationalized in FY25-26. The company projects that upon completion of its existing order book, it will have 200+ CT/MRI centres, cementing its position as one of Asia’s largest radiology players.

The Rajasthan project is expected to grow the network to 7 Reference Labs, 41 Mother Labs, 249 Satellite Labs & 5,000+ Collection Centres. Total assets as of March 31, 2026, stood at ₹18,237.16 million, compared to ₹12,815.95 million in the previous year.

Auditor and Regulatory Disclosures

The Statutory Auditors, MSKA & Associates LLP, issued an unmodified opinion on the audited standalone and consolidated financial results. The auditor's report included an emphasis of matter regarding assessment orders passed by the Income Tax Authorities for assessment years 2017-18 to 2023-24 under search assessment proceedings, resulting in a demand of ₹626.90 million. The company has filed appeals and deposited ₹102.77 million under protest, with management stating the demand is not tenable and not expected to have a material impact.

The board approved the re-appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27 to FY31, subject to shareholder approval.